Press Releases
Samsung Biologics records sales of KRW 78.1 billion and operating loss of KRW 15.4 billion in 2Q 2019
Samsung Biologics records sales of KRW 78.1 billion and operating loss of KRW 15.4 billion in 2Q 2019
Samsung Biologics Co.,Ltd. (CEO: Tae Han Kim) today announced its business performance for the second quarter in 2019.
The company posted quarterly sales of KRW 78.1 billion, operating loss of KRW 15.4 billion, and net loss of KRW 13.4 billion.
The sales were down by KRW 47.3 billion compared to the previous quarter, due to Slow-down(*) at Plant 2 for regular maintenance.
Operating profit improved by KRW 8 billion despite decrease in revenue and increased legal costs, as a result of internal innovation
activities and efforts to reduce costs. Net income increased by KRW 25.1 billion compared to the previous quarter due to the reduction
of unrealized gains and losses.
Compared to same quarter last year, sales decreased by KRW 47.3 billion (-37.7%). Operating profits fell by KRW 39.1 billion,
and net profit increased by KRW 6.1 billion due to improved business performance at subsidiary companies.
※ Samsung
Biologics Financial Result 2Q 2019
(Billion KRW)
|
|
'19. 2Q |
'19. 1Q |
QoQ |
'18. 2Q |
YoY |
|
Sales |
78.1 |
125.4 |
-47.3 |
125.4 |
-47.3 |
|
Operating Profit |
-15.4 |
-23.4 |
+8.0 |
23.7 |
-39.1 |
|
Net Profit |
-13.4 |
-38.5 |
+25.1 |
-19.5 |
+6.1 |
* Slow-Down :
Regular maintenance essential for biopharmaceutical manufacturing ? the plant operation rate temporarily decreases during this period.
Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once.
Samsung Biologics records sales of KRW 78.1 billion and operating loss of KRW 15.4 billion in 2Q 2019
Samsung Biologics Co.,Ltd. (CEO: Tae Han Kim) today announced its business performance for the second quarter in 2019.
The company posted quarterly sales of KRW 78.1 billion, operating loss of KRW 15.4 billion, and net loss of KRW 13.4 billion.
The sales were down by KRW 47.3 billion compared to the previous quarter, due to Slow-down(*) at Plant 2 for regular maintenance.
Operating profit improved by KRW 8 billion despite decrease in revenue and increased legal costs, as a result of internal innovation
activities and efforts to reduce costs. Net income increased by KRW 25.1 billion compared to the previous quarter due to the reduction
of unrealized gains and losses.
Compared to same quarter last year, sales decreased by KRW 47.3 billion (-37.7%). Operating profits fell by KRW 39.1 billion,
and net profit increased by KRW 6.1 billion due to improved business performance at subsidiary companies.
※ Samsung Biologics Financial Result 2Q 2019
(Billion KRW)
|
|
'19. 2Q |
'19. 1Q |
QoQ |
'18. 2Q |
YoY |
|
Sales |
78.1 |
125.4 |
-47.3 |
125.4 |
-47.3 |
|
Operating Profit |
-15.4 |
-23.4 |
+8.0 |
23.7 |
-39.1 |
|
Net Profit |
-13.4 |
-38.5 |
+25.1 |
-19.5 |
+6.1 |
* Slow-Down :
Regular maintenance essential for biopharmaceutical manufacturing – the plant operation rate temporarily decreases during this period.
Typically held every two years, activities essential to optimize productivity and efficiency of the plant and consumable parts replacements take place all at once.